Lung Cancer Patient´s Survival Treated with Chemotherapy

Authors

  • Gala Nausica Romero Moratalla Hospital General Universitario Carlos Manuel de Céspedes. Bayamo. Granma, Cuba.
  • Alarico Romero Moratalla Policlínico Bayamo Oeste. Bayamo. Granma, Cuba.
  • María Eugenia Moratalla Sosa Hospital General Universitario Carlos Manuel de Céspedes. Bayamo. Granma, Cuba.
  • Yusleidis Hidalgo Aparicio Hospital General Universitario Carlos Manuel de Céspedes. Bayamo. Granma, Cuba.

Keywords:

lung neoplasms/terapy, antineoplastic combined chemotherapy protocols/ therapeutic use.

Abstract

Lung cancer is a health problem in the world, the incidence has progressively increased over the past four decades, and most patients are diagnosed in advanced stages where non-small surgical treatment with curative intent in cancer cells and it is not possible, and in small cell cytotoxic response to primary treatment is short-lived if the diagnosis is made late. A retro-prospective cohort study of patients diagnosed with lung cancer who received chemotherapy in the Oncology service at General University Hospital Carlos Manuel de Cespedes during the years 2013-2015 in order to assess the evolution of patients suffering lung cancer treated with chemotherapy and determine the survival thereof. We obtained as main results that the average survival time was 240.83 days (95 % - 193.79 - 287.86 days), and it was higher for patients with partial response to treatment with 232.46 days. The progression was the most frequently detected event with 62.5 % for small cell and 44.11 % for non-small-cell tumors.

Downloads

Download data is not yet available.

References

1.Engels EA, Pfeiffer RM, Ricker W, Wheeler W, Parsons R, Warren JL. Use of surveillance, epidemiology, and end results-medicare data to conduct case-control studies of cancer among the US elderly. Am J Epidemiol [Internet]. 2011 [citado 17 Ene 2016]; 174(7):860–70. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3203375/.

2. Sun S, Schiller JH, Gazdar AF. Lung cancer in never smokers — a different disease. Nat Rev Cancer [Internet]. 2007 [citado 17 Ene 2016]; 7:778-90. Disponible en: http://www.nature.com/nrc/journal/v7/n10/full/nrc2190.html.

3. Spira A, Beane J, Shah V, Lui G, Schembri F, Yang X, et al. Effects of cigarette smoke on the human airway epithelial cell transcriptome. Proc Natl Acad Sci USA [Internet]. 2004 [citado 17 Ene 2016]; 101 (27):10143-8 . Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC454179/

4. Wender R, Fontham ETH, Barrera E, Colditz GA, Church TR, Ettinger DS, et al. American Cancer Society lung cancer screening guidelines. CA Cancer Journal Clinicians [Internet]. 2013 [citado 17 Ene 2016]; 63 (2):107–17. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3632634/

5. Unidad Nacional para el Control del Cáncer. Registro Nacional del Cáncer. La Habana; 2013.

6. Davidoff AJ, Tang M, Seal B, Edelman MJ. Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol [Internet]. 2010 [citado 21 Ene 2016]; 28(13):2191–7. Disponible en: http://jco.ascopubs.org/content/28/13/2191.long.

7. Iannettoni MD. Staging strategies for lung cancer. JAMA [Internet]. 2010 [citado 24 Ene 2016]; 304(20):2296–7. Disponible en: http://jama.jamanetwork.com/article.aspx?articleid=186942.

8. Mitka M. Targeted therapies take aim against lung cancer and melanoma. JAMA [Internet]. 2010 [citado 24 Ene 2016]; 304(6):624–6. Disponible en: http://jama.jamanetwork.com/article.aspx?articleid=186379.

9. Yang K, Wang YJ, Chen XR, Chen HN. Effectiveness and safety of bevacizumab for unresectable non-small-cell lung cancer: a meta-analysis. Clin Drug Investig. 2010; 30(4):229–41.

10. Goulart B, Ramsey S. A trial-based assessment of the cost-utility of bevacizumab and chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer. Value Health[Internet]. 2011[citado 24 Ene 2016]; 14(6):836–45. Disponible en: http://www.sciencedirect.com/science/article/pii/S1098301511014124.

11. Junya Z, Dhruv B, Stacy WG, Aileen BC, Weeks CJ, Schrag D. Carboplatin and Paclitaxel with vs without Bevacizumab in Older Patients with Advanced Non-Small-Cell Lung Cancer. JAMA [Internet]. 2012 April 18[citado 24 Ene 2016]; 307(15): 1593–601. http://jama.jamanetwork.com/article.aspx?articleid=1148151

12. Schuchert MJ, Schumacher L, Kilic A. Impact of angiolymphatic and pleural invasion on surgical outcomes for stage I non-small cell lung cancer. Ann Thorac Surg. 2011; 91(4):1059–65.

13. Agarwal M, Brahmanday G, Chmielewski GW, Welsh RJ, Ravikrishnan KP. Age, tumor size, type of surgery, and gender predict survival in early stage (stage I and II) non-small cell lung cancer after surgical resection. Lung Cancer. 2010; 68(3):398–402.

14. Antonoff MB, D’Cunha J. Non-small cell lung cancer: the era of targeted therapy. Lung Cancer: Targets and Therapy [Internet] 2012 [citado 24 Ene 2016]; 3: 31–41. DOI https://dx.doi.org/10.2147/LCTT.S16442.

15. Taratula O, Garbuzenko OB, Chen AM, Minko T. Innovative strategy for treatment of lung cancer: targeted nanotechnology-based inhalation co-delivery of anticancer drugs and siRNA. J Drug Target [Internet]. 2011[citado 24 Ene 2016];19(10): 900–14. http://www.tandfonline.com/doi/full/10.3109/1061186X.2011.622404

16. World Health Organization. Lyon, France: International Agency for Research on Cancer; Feb 3, 2014. Press Release No. 224. [Internet] [citado 24 Ene 2016]. Disponible en: http://www.iarc.fr/en/media-centre/pr/2014/pdfs/pr224_E.pdf

17. Eisenhauer EA, Therasse P, Bogaerts J, Schwatz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours. Revised RECIST guideline (version 1.1). European Journal of Cancer [Internet] 2009 [citado 22 Abr 2016]; 45:228-47. Disponible en: https://ctep.cancer.gov/protocoldevelopment/docs/recist_guideline.pdf

18. Pillai RN, Owonikoko TK. Small cell lung cancer: therapies and targets. Semin Oncol [Internet]. 2014 Feb [citado 22 Mar 2016]; 41(1):133-42. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4176613/

19. Siddiqi A, Bahrain H, Auerbach M. Experience with carboplatin and etoposide maintenance chemotherapy in patients with extensive stage small cell lung cancer. Lung Cancer: Targets and Therapy. 2011; 2: 41–5.

20. Sandler A, Gray R, Perry MC. Paclitaxel–carboplatin alone or with bevacizumab for non–small-cell lung cancer. N Engl J Med [Internet] 2006[citado 24 Abr 2016];355:2542-50. Disponible en: http://www.nejm.org/doi/full/10.1056/NEJMoa061884

21. De Castro J, González-Larriba JL, Vázquez S. Long-term survival in advanced non-squamous NSCLC patients treated with first-line bevacizumab-based therapy. Clin Transl Oncol [Internet]. 2016 Jul 1. [citado 20 Jul 2016]. Disponible en: http://link.springer.com/article/10.1007%2Fs12094-016-1527-8.doi:10.1007/s12094-016-1527-8.

Downloads

Published

2016-11-11

How to Cite

1.
Romero Moratalla GN, Romero Moratalla A, Moratalla Sosa ME, Hidalgo Aparicio Y. Lung Cancer Patient´s Survival Treated with Chemotherapy. RM [Internet]. 2016 Nov. 11 [cited 2025 Jun. 25];20(4):797-809. Available from: https://revmultimed.sld.cu/index.php/mtm/article/view/276

Issue

Vol. 20 No. 4 (2016)

Section

ARTÍCULOS ORIGINALES

License

Avisos de derechos de autor propuestos por Creative Commons

1. Política propuesta para revistas que ofrecen acceso abierto

Aquellos autores/as que tengan publicaciones con esta revista, aceptan los términos siguientes:
  1. Los autores/as conservarán sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, el cuál estará simultáneamente sujeto a la Licencia de reconocimiento de Creative Commons que permite a terceros compartir la obra siempre que se indique su autor y su primera publicación esta revista.
  2. Los autores/as podrán adoptar otros acuerdos de licencia no exclusiva de distribución de la versión de la obra publicada (p. ej.: depositarla en un archivo telemático institucional o publicarla en un volumen monográfico) siempre que se indique la publicación inicial en esta revista.
  3. Se permite y recomienda a los autores/as difundir su obra a través de Internet (p. ej.: en archivos telemáticos institucionales o en su página web) antes y durante el proceso de envío, lo cual puede producir intercambios interesantes y aumentar las citas de la obra publicada. (Véase El efecto del acceso abierto).